Why the study?
Trimetazidine improves clinical outcomes in chronic heart failure and stable CAD, but its efficacy in acute myocardial infarction patients undergoing PCI had not been comprehensively evaluated.
Does trimetazidine improve cardiac biomarkers and function in acute myocardial infarction patients undergoing percutaneous coronary intervention?
Population
401 Chinese AMI patients undergoing PCI
Comparison
Trimetazidine vs control
Design
Blinded randomized controlled trial
Follow-up
6 months after discharge
Authors
Loading...
TMZ may reduce post-PCI myocardial injury markers in AMI; leaves open effects on hard clinical outcomes.
Does trimetazidine improve cardiac biomarkers and function in acute myocardial infarction patients undergoing percutaneous coronary intervention?
Trimetazidine added to standard therapy in AMI patients undergoing PCI may reduce myocardial injury biomarkers and improve left ventricular ejection fraction.
Tang et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: